Resveratrol Ameliorates PTZ-Induced Seizure Activity and Diaphragm Muscle Dysfunction by Regulating Calcium Handling and Apoptotic Pathways in Rats.

Authors

Ahmet Akkoca, Ömer Ünal, Nilüfer Akgün-Ünal, Emre Soner Tiryaki, Elif Gülbahçe-Mutlu, Mustafa Ayyıldız

Published in

Molecular neurobiology. Volume 63. Issue 1. Jul 09, 2026. Epub Jul 09, 2026.

Abstract

This study aimed to investigate the chronic effects of epilepsy, a common health problem, on the diaphragm muscle and the therapeutic potential of resveratrol against these effects. Thirty-two adult male Wistar rats were divided into four groups (n = 8): Sham, resveratrol (Res, 5 mg/kg/day), pentylenetetrazol (PTZ), and PTZ + Res. Seizure activity and frequency in the epileptic groups were monitored via electrocorticography (ECoG) recordings. Diaphragmatic mechanical activities were evaluated through basal contractility and frequency-dependent fatigue parameters. Molecular analyses focused on calcium homeostasis, including tissue calcium (Ca²⁺) levels and sarcoplasmic/endoplasmic reticulum Ca²⁺-transporting ATPase 2 (Atp2a2) mRNA expression, as well as apoptotic markers (Casp-3, Casp-9, Bax, and Bcl-2). Our results indicated a significant suppression of diaphragmatic contractile parameters induced by chronic seizures, as verified by ECoG. This suppression was a consequence of Atp2a2 inhibition, Ca²⁺ overload, and increased apoptotic activity. On the other hand, resveratrol treatment exhibited a therapeutic effect toward restoring basal mechanical activities of the diaphragm and gaining resistance against fatigue. This effect was mediated through the reorganization of Ca²⁺ homeostasis and the inhibition of increased apoptotic activity. In conclusion, resveratrol demonstrated promising results in improving diaphragmatic functions in individuals with epilepsy, thanks to its role in suppressing epileptic activity, regulating Ca²⁺ and Atp2a2 management, and its antiapoptotic effects.

PMID:
42426356
Bibliographic data and abstract were imported from PubMed on 10 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.